Glucose-6-phosphate dehydrogenase expression is correlated with poor clinical prognosis in esophageal squamous cell carcinoma.
Increasing evidence has demonstrated that glucose-6-phosphate dehydrogenase (G6PD), a key metabolic enzyme, participating in pentose phosphate pathway (PPP), is tightly associated with development and progression of a variety of tumors. Here, we reported expression of G6PD and its association with the prognosis of the patients with esophageal squamous cell carcinoma (ESCC). The results revealed significantly elevated G6PD mRNA and protein expressions in ESCC tissues compared with normal tissues (P < 0.05). Furthermore, high G6PD expression was tightly associated with histological grade, TNM staging and lymph node metastasis (P < 0.05), but not related to the patients' age and gender (P > 0.05). Importantly, the survival time of G6PD-positive patients was markedly lower than that of G6PD-negative patients (P < 0.05). Most notably, Cox multivariate assay demonstrated that G6PD was an independent prognostic factor for the patients with ESCC. In conclusion, G6PD may be a novel predictor for the prognosis of the patients with ESCC.
Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, PR China.
Xin
X
Wang
School of Basic Medical Sciences, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, 450000, PR China.
XiaoJuan
X
Li
Laboratory for Cell Biology, School of Life Sciences of Zhengzhou University, Zhengzhou, Henan, 450001, PR China.
XiaQing
X
Zhang
Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, PR China.
RuiTai
R
Fan
Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, PR China.
Hao
H
Gu
Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, PR China.
YongGang
Y
Shi
Laboratory for Cell Biology, School of Life Sciences of Zhengzhou University, Zhengzhou, Henan, 450001, PR China. Electronic address: liuht1230@126.com.
HongTao
H
Liu
D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D004947:Esophagus / Q000378:metabolism* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D012333:RNA, Messenger; D005954:Glucosephosphate Dehydrogenase
Esophageal squamous cell carcinoma; Glucose-6-phosphate dehydrogenase; Pentose phosphate pathway; Prognostic factor